# BPDO-1603 Intervention Trial in Patients With Moderate-to-severe Alzheimer's Disease

> **NCT04229927** · PHASE3 · UNKNOWN · sponsor: **Hyundai Pharmaceutical Co., LTD.** · enrollment: 712 (estimated)

## Conditions studied

- Moderate-to-severe Alzheimer's Disease

## Interventions

- **DRUG:** BPDO-1603

## Key facts

- **NCT ID:** NCT04229927
- **Lead sponsor:** Hyundai Pharmaceutical Co., LTD.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-02-27
- **Primary completion:** 2022-02-28
- **Final completion:** 2023-03-01
- **Target enrollment:** 712 (ESTIMATED)
- **Last updated:** 2020-04-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04229927

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04229927, "BPDO-1603 Intervention Trial in Patients With Moderate-to-severe Alzheimer's Disease". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04229927. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*